Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which may play an important role in inflammatory and immune responses. Stelara® is indicated for range of immune medicated inflammatory diseases and has recorded global sales of US$ 19 billion of which US$D 3.2 billion sales coming from Europe as per IQVIA MAT Jun'24 data.

Joe Dunford, VP of Speciality Brands stated, "Accord is committed to becoming a significant player in the autoimmune space, and we are delighted that the European Commission (EC) has granted marketing authorisation for our fifth biosimilar in Europe, Imuldosa®. This approval ensures that patients have access to high-quality therapies in Europe and beyond. We remain dedicated to advancing our biosimilar pipeline, with the goal of launching 20 biosimilars by 2030.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/accord-healthcare-is-granted-marketing-authorisation-for-imuldosa-ustekinumab-biosimilar-to-stelara-302331641.html